Antibodies and cancer cells attacking the body.
Dividing and growing cancer cells.
T-Lymphocytes cells attacking cancer cell after becoming revitalized by PEMF therapy. They destroy or normalize cancer cells and other altered cells by releasing cyto-toxic granules.
Healthy red blood cells flowing in artery after becoming cancer free by the use of PEMF therapy.
Cancer
The fight with cancer may never be over. Current medical therapies have limited effectiveness. Complete remission is rarely achieved. A cure is being strived for, but with so many different types and subtypes of cancer it can sometimes feel like a lost cause. This is not to say a cure isn’t worth fighting for. Cancer is one of the leading causes of death in this world and it affects so many of us. We need more ways of fighting the disease.
PEMF and Cancer
PEMF therapy has numerous advantages for those suffering from cancer including, non-invasiveness, safety, lack of toxicity for non-cancerous cells and the possibility of being combined with other available therapies. PEMF therapy has been extensively studied in vitro using various human cancer cell lines. These studies have shown that PEMF therapy may exert proliferative inhibition and mitotic spindle disruption and block the development of neovascularization required for tumor supply. While chemotherapy is not specific to cancer cells and targets all rapidly dividing cells, PEMFs exert selective cytotoxic effect on neoplastic cells making this therapy a highly promising strategy.
A study which lasted three days assessed the effect of PEMF therapy on human breast adenocarcinoma cells. The study showed that PEMF’s were cytotoxic to the cancerous cells, but not to normal breast tissue. Longer studies are currently ongoing and much needed. PEMF’s are by no means a one stop cure for cancer. But they have shown much potential as a treatment option with no harmful side effects reported.
References :
Mechanisms and therapeutic effectiveness of pulsed electromagnetic field therapy in oncology. Cancer Medicine 2016. Maria Vadalà, Julio Cesar Morales-Medina, Annamaria Vallelunga, Beniamino Palmieri, Carmen Laurino1 & Tommaso Iannitti